Background and Purpose: Hitherto, treatment of acute cerebral hemorrhage with intravenous glycerol has not been evaluated in rigorous clinical studies with sufficient patient numbers.
patients, 8 glycerol was shown to increase cerebral perfusion through hemodilution and reduction of raised intracranial pressure. Moreover, clinicians have often used glycerol empirically in cerebral hemorrhage, even though hitherto there have been no adequate controlled trials to evaluate its possible benefits.
The current double-blind, placebo-controlled, randomized trial was undertaken to determine whether treatment of acute SSIH with intravenous glycerol has a clinically significant favorable influence on mortality and morbidity over the ensuing 6 months.
Subjects and Methods

Case Selection
Consecutive patients aged 30-80 years with no history of stroke were entered into the study if SSIH was confirmed on computed tomography (CT). Informed consent was obtained from the patients or their close relatives. The exclusion criteria were posterior fossa hemorrhage, hemorrhage resulting from aneurysm or arteriovenous malformation, any other condition warranting neurosurgery, or concomitant medical problems including collagen-vascular disease, bleeding diathesis, and anticoagulant therapy. Patients commencing trial medication were to have it withdrawn if they required neurosurgical treatment or if it was deemed necessary by the attending neurologist. However, outcome and neurological scores were assessed in all patients because analysis was on an intention-to-treat basis.
Methods and Analysis
Clinical method. History and physical findings, including detailed neurological assessment, were recorded on admission. In particular, the time from onset of symptoms to admission, history of hypertension, vascular disease, cardiac arrhythmia, diabetes mellitus, smoking, drug treatment, and relevant family history were noted. At each examination, neurological variables were documented without knowledge of the treatment administered. The scoring system of the Scandinavian Stroke Study Group (SSScand) 9 and score on the Glasgow Coma Scale (GCS) 10 were used to assess patients on admission; before treatment (on the first day they received trial medication) and on days 3, 7, 14, 21, and 28; and then monthly for 5 months. One month after entering the trial and at monthly intervals thereafter, the overall score for activities of daily living was assessed by using the Barthel Index. 11 The cause of death (brain herniation, pneumonia, septicemia, airway obstruction, recurrent stroke, and others) was ascertained as far as possible.
Laboratory parameters. The following were checked at the initial examination: complete blood count (hemoglobin concentration, packed cell volume, and white cell, platelet, and reticulocyte counts), plasma glucose, serum biochemical indexes, and electrocardiogram. The complete blood count and serum biochemical indexes were repeated on day 7.
Computed tomographic method. SSIH was confirmed by noncontrast brain CT using the GE 9800 system with standard window settings and 10-mm slices from the orbitomeatal line to the vertex. CT was performed as soon as possible and not later than 24 hours following admission and was repeated between days 7 and 10 and whenever warranted by the patient's clinical condition. The size of the lesion (volume of hemorrhage with and without edema) was measured by computer at the physician's diagnostic console.
Other investigations. Cerebral angiography was performed in patients in whom an aneurysm or arteriovenous malformation was suspected and in patients with unusual sites of bleeding.
Treatment. Due to differing prognoses depending on the initial severity of the stroke, patients were stratified according to the pretreatment GCS score: coma (score of 3-7), semicoma (score of [8] [9] [10] [11] , and alert (score of 12-15). Active treatment was 500 ml of 10% glycerol (generic) in physiological saline, and placebo was 500 ml of physiological saline. Each treatment was administered intravenously over 4 hours for 6 consecutive days.
Design and analysis. Based on previous statistics, 1213 240 patients were expected to enter the trial over 24 months. A group sequential approach 14 was adopted, and treatment was allocated according to a stratified randomized block design. Differences from pretreatment values (for GCS score, prognostic and long-term items on SSScand) or initial findings (score on Barthel Index) were expressed as 8 scores and used as measures of outcome. See Appendix for definition of symbols. 'Period from onset of symptoms to start of trial medication. t Angina and/or myocardial infarction.
Analyses were performed on all patients (scoring death as 0 on the clinical scales) and on survivors only. A subsidiary analysis was undertaken on the alert subgroup. Patients whose trial medication was stopped when gross hemolysis was suspected were also followed up and included in the analyses on an intention-to-treat basis.
The 1-month long-term 8 score was selected as the monitoring variable. One interim analysis was planned after the entry of 120 patients, using the latter variable and an overall significance level of 5% for any difference (A) in the mean 8 scores. Assuming that the 5 scores follow a normal distribution across strata within each treatment group, the power is 0.95 at an absolute value of A of Via, where <ris the (common) SD of the 8 scores.
In practice Vkris about 5-7, and this range was taken as the measure of clinical significance. Parametric and nonparametric methods were employed for the interim and final analyses. Follow-up analyses of corresponding variables were performed on the respective 5 scores at 2, 3, 4, 5, and 6 months, results at 6 months being taken as the clinically definitive assessment. The SAS package 15 was used for the analyses. For ethical reasons, the trial was also subjected to continuous informal monitoring of death rate and side effects (hemolysis).
Results
After 120 patients were recruited, the interim analysis did not reveal a significant result. The trial was then continued on its second phase but was not run to final completion because the probability that A was >5 for the long-term 8 scores had become negligible based on a Bayes posterior normal distribution calculation (see Appendix and Table 4 ). Patients randomized to the two Surviving 67(1) 60 (7) 57 (1) 52 ( Values are number of patients. In glycerol group death was attributed to brain stem herniation in 27 patients (only six of whom were alert at entry), pneumonia in two, septicemia in one, myocardial infarction in two, and unknown or other causes in five. Corresponding figures for placebo group were 20 (three alert at entry), four, three, three, and three. Numbers in parentheses refer to patients who developed gross hemoglobinuria, warranting discontinuation of trial medication. treatment groups (216 in all) were comparable with respect to age, sex distribution, and prior clinical features (Table 1) and were recruited over 31 months. No patient was referred for neurosurgery after randomization. Table 2 summarizes the status of all patients 6 months after SSIH, with respect to survival, deaths, and loss to follow-up. For all accountable trial patients treated with glycerol or placebo, the neurological and rehabilitation scores at 6 months are summarized in Table 3 . Table 4 is a summary of the predictive analysis based on the 6-month long-term scores. The analysis shows that, using this regimen of glycerol therapy, no clinically or statistically significant difference in neurological scores (outcome) could be expected.
Hemolysis (usually subclinical) was the only drug side effect observed. Table 2 shows the respective numbers of patients in whom placebo or glycerol treatment was withdrawn when gross hemoglobinuria was suspected. Table 5 summarizes pertinent hematologic findings for all 216 patients entering the trial. For patients surviving for up to 7 days, the mean reductions from pretreatment hemoglobin values were 0.54 and 0.12 g/dl following treatment with glycerol and placebo, respectively. Thus, neither the absolute nor the relative changes in hemoglobin concentration could be regarded as clinically significant. 16 Discussion Hitherto, studies purporting to evaluate the possible beneficial effect of intravenous glycerol in patients with acute stroke have yielded contradictory and inconclusive results. 17 " 25 Commonly, there was no attempt to distinguish hemorrhagic from ischemic episodes (especially in earlier trials), and if attempted, objective confirmation of the diagnosis with CT was lacking or inconsistent.
17 " 24 The study by Frei et al, 25 in which pretreatment CT was performed on all patients, concerned ischemic stroke. Other important shortcomings in the design and execution of these investigations included failure to stratify patients according to stroke severity (anticipated prognosis), prolonged delays before initiating treatment, limited measures of outcome, exclusion of the most severely affected patients, too few patients, and insufficient period of follow-up.
By contrast, our trial entailed CT confirmation of SSIH, inclusion of both mild and severe cases, corresponding stratification based on level of consciousness (GCS score), and inclusion of only patients with onset of symptoms in the 24 hours before admission. In the final •Though 6-month follow-up scores were available, a few patients did not have initial (1-month) Barthel Index score for a variety of logistic reasons. analysis data were available for 216 patients, nearly the same number as had been projected, and those assigned to glycerol and placebo treatment had very similar pretreatment clinical profiles (Table 1) . Furthermore, our measures of outcome included the death rate, a series of formal neurological deficit scores, and objective evaluation of rehabilitation status, all followed up for 6 months.
The only important adverse effect of treatment we encountered was intravascular hemolysis. A critical study of the extent to which it affected patients entering our trial and the likely mechanism were reported elsewhere. 16 The latter in vivo and in vitro investigation revealed that hemolysis probably resulted from glycerol at the site of infusion rapidly entering erythrocytes and destroying them in more central veins due to osmotically induced swelling beyond a critical limit. Thus, so long as the infusion rate did not exceed 125 ml/hr (even temporarily), clinically significant hemolysis did not ensue. The use of glycerol solutions containing small amounts of fructose may also overcome hemolysis to some extent, there being in vitro evidence that osmotic fragility can be mitigated by this means. 26 Japanese clinicians have infused such mixtures into patients very rapidly, apparently without ill effect. 27 Following our preliminary experience, special care was taken to avoid excessive infusion rates; it was gratifying that after 7 days, the mean reduction of hemoglobin concentration in patients receiving glycerol in our study was much smaller (about Vi) than that reported by Frei et al. 25 Indeed, following 6 days of glycerol or placebo treatment, mean reductions encountered in our patients were 0.54 and 0.12 g/dl, respectively; the difference of only 0.4 g/dl was statistically but not clinically significant (Table 5) . Furthermore, such subclinical reductions in hemoglobin concentration after infusion of glycerol in saline may be attributed to a While our overall results show no clinically or statistically significant difference in outcome between patients treated with glycerol or saline, there were too few comatose and semicomatose patients to make any kind of reliable independent estimate of the effect of treatment within these strata. Conceivably, different treatment regimens (doses, rates of infusion, continuous versus intermittent administration, earlier initiation of therapy) might have had a more favorable impact, but this remains to be proved. However, as already alluded to, more rapid infusion of glycerol could pose problems due to an alarming degree of intravascular hemolysis. Regarding conventional regimens of intravenous glycerol, our relatively large trial in patients with all grades of acute SSIH provides no evidence in support of such therapy.
Appendix
Definition of 8 Score
For individual; in group i (i=l for glycerol, i'=2 for placebo) define S tl as (score at month A:)-(pretreatment score). For example, in Table 4 k=6 and score=long-term score. Therefore, A,=( X 8,j)/«, estimates the mean change A, in group i, and A=A,-A 2 estimates the mean difference A=A 1 -A 2 between groups.
Bayes Posterior Density Calculations
The 5 scores here are based on the 6-month long-term scores in Table 4 'Statistically significant difference from 0 and from value in placebo group (p<0.02; 95% confidence interval -0.82 to -0.26 g/dl). Among individual patients in placebo and glycerol groups, largest hemoglobin reductions were 2.6 and 3.1 g/dl, respectively.
•- (7) p(A>x)=l-where <t>(z)= f z --==e' 2 dt is the standard normal cumulative distribution function.
